MSH6 and ovarian cancer: In Supplementary Figure 2A, MSH6’s high expression was linked with poor PFS (Progression-free survival) (P=0.0034), OS (P=0.022) and PPS (Post-progression survival) (P=0.048) in patients with ovarian cancer.